JNJ-26483327, also known as BGB102, is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted tyrosine kinase inhibitor JNJ-26483327 binds to and inhibits several members of the epidermal growth factor receptor (EGFR) family, including EGFR, HER2 and HER4; Src family kinases (Lyn, Yes, Fyn, Lck and Src); and vascular endothelial growth factor receptor type 3 (VEGFR3).
Ibafloxacine is a synthetic fluoroquinolone antibiotic that was first introduced in the market in 1993. It is used to treat various bacterial infections, including respiratory tract infections, urinary tract infections, and skin infections. Ibafloxacine is a broad-spectrum antibiotic that works by inhibiting the bacterial DNA gyrase enzyme, which is essential for bacterial DNA replication.